IntelliPharmaCeutics Intl (IPCI) Given a $3.00 Price Target by HC Wainwright Analysts
IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) has been assigned a $3.00 price target by research analysts at HC Wainwright in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 279.75% from the stock’s current price.
A number of other equities research analysts have also recently issued reports on the stock. Maxim Group set a $2.00 price objective on shares of IntelliPharmaCeutics Intl and gave the stock a “buy” rating in a report on Friday, February 9th. Zacks Investment Research cut shares of IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a report on Wednesday, January 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $2.53.
Shares of IntelliPharmaCeutics Intl (IPCI) opened at $0.79 on Monday. The stock has a market cap of $23.30, a price-to-earnings ratio of -2.26 and a beta of 1.06. IntelliPharmaCeutics Intl has a fifty-two week low of $0.70 and a fifty-two week high of $2.92.
IntelliPharmaCeutics Intl Company Profile
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.